Heart Council Meeting Switches to Zoom, Date Advanced
Published Date: 1/28/2026
Notice
Summary
Heads up! The National Heart, Lung, and Blood Advisory Council meeting got a makeover: it’s now happening earlier on March 25, 2026, switching from in-person to virtual, and moving to a new Bethesda address. This change affects anyone interested in the meeting and means you can join online instead of traveling. Some parts of the meeting will still be private, so mark your calendars and get ready to tune in from wherever you are!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 1 costs, 2 mixed.
Meeting date moved to March 25, 2026
The National Heart, Lung, and Blood Advisory Council meeting was moved from October 29, 2026 to March 25, 2026. If you planned to attend on October 29, 2026, you will need to adjust your schedule to the new date, March 25, 2026.
Meeting changed from in-person to virtual
The meeting format changed from a regular in-person meeting to a virtual meeting on March 25, 2026. You can join online instead of traveling to Bethesda, which avoids travel time and expenses if you planned to attend in person.
Physical location updated in Bethesda
The meeting location was changed from Claude D. Pepper Building, 31 Center Drive, Bethesda, MD 20892 to 6701 Rockledge Drive, Bethesda, MD 20892. If you planned to attend any in-person portion, note the new address.
Portions of meeting closed to public
The meeting on March 25, 2026 is partially closed to the public, meaning some sessions will not be open for public attendance or viewing. If you want to observe all proceedings, you will not be able to attend the closed portions.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2026-01687, Formations of, Acquisitions by, and Mergers of Bank Holding Companies
Some companies want to become bank holding companies or merge with banks, and the Federal Reserve is checking their applications. If you have thoughts, you can send comments by February 27, 2026. These changes could shake up who controls certain banks, so it’s a big deal for the banking world and anyone who follows it.
Next: 2026-01690, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early 2026 to review and decide on important grant applications related to pain research, cell biology, and cancer studies. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or new costs.